GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » EBITDA Margin %

OncoSil Medical (ASX:OSL) EBITDA Margin % : -1,568.85% (As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is OncoSil Medical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. OncoSil Medical's EBITDA for the six months ended in Dec. 2024 was A$-7.20 Mil. OncoSil Medical's Revenue for the six months ended in Dec. 2024 was A$0.46 Mil. Therefore, OncoSil Medical's EBITDA margin for the quarter that ended in Dec. 2024 was -1,568.85%.


OncoSil Medical EBITDA Margin % Historical Data

The historical data trend for OncoSil Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSil Medical EBITDA Margin % Chart

OncoSil Medical Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -4,811.27 -4,917.67 -3,034.51 -2,385.11

OncoSil Medical Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,575.46 -3,711.26 -7,520.45 -1,322.38 -1,568.85

Competitive Comparison of OncoSil Medical's EBITDA Margin %

For the Medical Devices subindustry, OncoSil Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSil Medical's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where OncoSil Medical's EBITDA Margin % falls into.


;
;

OncoSil Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

OncoSil Medical's EBITDA Margin % for the fiscal year that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2024 )/Revenue (A: Jun. 2024 )
=-12.331/0.517
=-2,385.11 %

OncoSil Medical's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-7.201/0.459
=-1,568.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSil Medical  (ASX:OSL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


OncoSil Medical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of OncoSil Medical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSil Medical Business Description

Traded in Other Exchanges
N/A
Address
7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.

OncoSil Medical Headlines

No Headlines